Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Panel Calls On FDA To Review Safety Of Opioid Painkillers

July 14, 2017 By Carla K. Johnson, Associated Press

The U.S. Food and Drug Administration should review the safety and effectiveness of all opioids, and consider the real-world impacts the powerful painkillers have, not only on patients, but also on families, crime and the demand for heroin.

That’s the conclusion of a sweeping report Thursday from the National Academies of Sciences, Engineering, and Medicine. It urges the FDA to bolster a public health approach that already has resulted in one painkiller being pulled from the market. Last week, the maker of opioid painkiller Opana ER withdrew its drug at the FDA’s request following a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles to inject the pills.

“Our recommendation is for a much more systematic approach, integrating public health decision-making into all aspects of opioid review and approval,” says Dr. Aaron Kesselheim of Harvard Medical School, a member of the report committee. “It would be an ambitious undertaking.”

The report details how two intertwining epidemics — prescription painkillers and heroin — led to the worst addiction crisis in U.S. history and provides a plan for turning back the tide of overdose deaths.

Prescribed, legal drugs are a gateway to illicit drugs for some, the report says. Other users start with pills diverted to the black market. Crush-resistant pills and other restrictions can have unintended consequences, shifting use to heroin and illicit fentanyl.

This Feb. 19, 2013 file photo shows hydrocodone-acetaminophen pills, also known as Vicodin, arranged for a photo at a pharmacy in Montpelier, Vt. On Thursday, July 13, 2017, the National Academies of Sciences, Engineering and Medicine released a report saying the U.S. Food and Drug Administration should review the safety and effectiveness of all opioid painkillers. (AP Photo/Toby Talbot, File)

The epidemic’s broad reach into rural and suburban America “has blurred the formerly distinct social boundary between use of prescribed opioids and use of heroin and other illegally manufactured ones,” the report says.

The authors say it’s possible to stem the crisis without denying opioids to patients whose doctors prescribe them responsibly. But long-term use of opioids by people with chronic pain should be discouraged because it increases dangers of overdose and addiction.

Requested by the FDA last year under the Obama administration, the report was greeted by FDA Commissioner Dr. Scott Gottlieb, a Trump appointee. Gottlieb said in a statement that the opioid epidemic is his “highest immediate priority” and he “was encouraged to see that many of (the) recommendations for the FDA are in areas where we’ve already made new commitments.”

Still, no immediate review of opioids as a class of drugs is planned by the FDA, other than the agency’s routine safety surveillance. Gottlieb said the FDA re-evaluates the safety of approved drugs with post-market information required from drugmakers and other sources.

“We will continue to consider what additional information is needed to ensure we have the right data to make important, science-based decisions,” he said.

Beyond the FDA, the report recommends:

—Better access to treatment for opioid addiction, including use of medications such as buprenorphine, in settings including hospitals, prisons and treatment programs. (The revised Senate Republican health care bill released Thursday includes $45 billion for states to use for addiction treatment and other responses to the opioid crisis, a boost over the $2 billion in the initial bill.)

—Year-round programs that allow people to return unused opioids to any pharmacy at any time, rather than only at occasional events. Some pharmacies, including Walgreens, have installed kiosks where people can get rid of pills.

—Insurers pay for pain control that goes beyond opioids to include non-drug treatment. The report doesn’t specify which treatments insurers should cover, but does outline what early evidence exists for acupuncture, physical therapy, cognitive-behavioral therapy and mindfulness meditation, calling them “powerful tools.”

—More research on the nature of pain and dependency on opioids and development of new non-addictive treatments.

Related Articles Read More >

Logos of Creo Medical and Intuitive
Creo Medical inks collaboration agreement with Intuitive
Lazurite ArthroFree wireless surgical camera system Minnetronix Medical
How Minnetronix Medical helped Lazurite with its wireless surgical camera
Medtronic Hugo robot-assisted surgery system
The road to a robot: Medtronic’s development process for its Hugo RAS system
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech